Clinical Trial Search

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 3 Participants

Primary: KCOT Volume (Greatest Dimension) — 3; 3.8; 0; 2.6 centimeter

Primary: Primary Safety Endpoint - Composite Safety Endpoint Based on MACCE — 25 Participants

Primary: Periodontal Pocket Depth (PD) Change From Baseline at 6 Months — -1.046; -1.114; -1.177 millimeters — p=0.297

Primary: Complete Response Rate — 12 Participants

Primary: Visual Analog Scale Pain Score — 16; 16 mm

Primary: Change in Airway Reactivity From Baseline (Visit 1) and 4 Weeks (Visit 2) — 3.0; 3.2; 5.3; 4.3 mg/mL

Primary: Opioid Consumption — 287.0; 281.1 morphine equivalents

Primary: Inventory of Complicated Grief - Revised (ICG-R) — 93.15; 93.10 score on a scale

Primary: The Number of Patients With Severe Adverse Events and Adverse Reactions — 0 Participants

Primary: Procedure Success Rate of LithoVue Ureteroscope System at 4Weeks4Weeks ± 7 Days From Procedure — 100 percentage of participants

Primary: Assessment of Treatment Related Adverse Events (AEs). — 0; 0; 0; 1 Patients with any DLT

Primary: Sensitivity of Scanning a/LCI Probe to Detect Cervical Dysplasia as Measured by Percentage of Correctly Identified Positive Biopsies — 90.3; 100.0 percentage of correct…

Primary: Percent Change From Baseline in Seizure Frequency Per 28 Days During the Maintenance Period — 3.11; -27.76 percent change — p=0.0007

Primary: Percentage of Subjects With Any Respiratory Adverse Event — 38; 24; 24; 23 Participants